Usual Apixaban Dosing OK With One Dose-Reduction Criterion

This article originally appeared here.
Share this content:
Usual Apixaban Dosing OK With One Dose-Reduction Criterion
Usual Apixaban Dosing OK With One Dose-Reduction Criterion

FRIDAY, July 29, 2016 (HealthDay News) -- For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online July 27 in JAMA Cardiology.

John H. Alexander, M.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues analyzed data on 17,322 participants from the ARISTOTLE trial. Of patients with one or no dose-reduction criteria assigned to receive the 5 mg twice daily dose of apixaban or warfarin, 3,966 had one dose-reduction criterion.

The researchers found that patients with one dose-reduction criterion had higher rates of stroke or systemic embolism and major bleeding compared to those with no dose-reduction criteria. Similar benefits were seen for 5 mg twice daily apixaban versus warfarin on stroke or systemic embolism among patients with one (hazard ratio [HR], 0.94; 95 percent confidence interval [CI], 0.66 to 1.32) or no dose-reduction (HR, 0.77; 95 percent CI, 0.62 to 0.97) criterion (P for interaction = 0.36). Benefits were also similar for major bleeding (HRs, 0.68 [95 percent CI, 0.53 to 0.87] and 0.72 [95 percent CI, 0.60 to 0.86], respectively) (P for interaction = 0.71). Patterns were similar for each dose-reduction criterion and across the spectrum of age, body weight, and creatinine level and clearance.

"Patients with atrial fibrillation and isolated advanced age, low body weight, or renal dysfunction have a higher risk of stroke or systemic embolism and major bleeding but show consistent benefits with the 5 mg twice daily dose of apixaban versus warfarin compared with patients without these characteristics," the authors write. "The 5 mg twice daily dose of apixaban is safe, efficacious, and appropriate for patients with only one dose-reduction criterion."

Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb and Pfizer, which manufacture apixaban and funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

24-Hour Primary Care Clinics Would Improve Continuity of Care

24-Hour Primary Care Clinics Would Improve Continuity of ...

Model involving multiple doctors working shifts in their own clinic offers many benefits

Repeat BP Reading Needed in Children With Initial High Result

Repeat BP Reading Needed in Children With Initial ...

Based on initial reading, more than half of children would have incorrect classification

Brochure Can Improve Opioid Disposal Rates After Surgery

Brochure Can Improve Opioid Disposal Rates After Surgery

Patients more likely to dispose of unused opioids after getting information and recommendations

is free, fast, and customized just for you!

Already a member?

Sign In Now »